Skip to main content
. 2023 Jan 19;14(1):39. doi: 10.1038/s41419-023-05580-y

Fig. 7. Schematic model of the activated PKG I attenuates EGF-induced EGFR/MAPK/ERK signaling in ovarian cancer.

Fig. 7

By binding to EGFR, the activated PKG I inhibit the expression of the EGFR/MAPK/ERK pathway and thereby decreases the expression of nuclear phosphorylated ERK1/2, ultimately leading to suppressed cell growth and metastasis in human EOC.